• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»accelerated approval

Partner Therapeutics’ zenocutuzumab data adds nuance to progression-driven treatment decisions in NRG1-positive lung cancer

By Pallavi Madhiraju on February 22, 2026   Pharma & Biotech  

Partner Therapeutics’ zenocutuzumab data adds nuance to progression-driven treatment decisions in NRG1-positive lung cancer

Find out how zenocutuzumab treatment beyond progression could change care for NRG1 fusion-positive lung cancer and what clinicians should watch next.

Why Deciphera Pharmaceuticals’ tirabrutinib NDA matters for the future of CNS lymphoma therapy

By Pallavi Madhiraju on February 18, 2026   Pharma & Biotech  

Why Deciphera Pharmaceuticals’ tirabrutinib NDA matters for the future of CNS lymphoma therapy

FDA accepts tirabrutinib NDA for relapsed or refractory PCNSL. Find out what this means for CNS lymphoma treatment and regulatory strategy.

Diamyd Medical fast-tracks type 1 diabetes Phase 3 trial after FDA alignment on earlier efficacy readout

By Pallavi Madhiraju on January 4, 2026   Pharma & Biotech  

Diamyd Medical fast-tracks type 1 diabetes Phase 3 trial after FDA alignment on earlier efficacy readout

Find out how Diamyd Medical is accelerating its type 1 diabetes Phase 3 trial after FDA alignment—what this means for approval, adoption, and risk.

Recent Posts

  • AACR 2026: SAGA Diagnostics pushes Pathlight MRD deeper into metastatic breast and ovarian cancer
  • Agenus AACR 2026 data show immune reprogramming signal in PD-1 refractory gastroesophageal cancer
  • AACR 2026: Can Zai Lab’s zocilurtatug pelitecan change the treatment picture for small cell lung cancer brain metastases?
  • How JANX014 expands Janux Therapeutics’ tumor-activated platform strategy in prostate cancer immunotherapy
  • What Medicus Pharma Ltd.’s SkinJect application signals for Hedgehog pathway-driven cancers
  • Why Bioxodes’ adaptive trial strategy could accelerate approval timelines in stroke therapeutics
  • What Kura Oncology’s latest data reveals about resistance biology in kidney cancer
  • Can Fate Therapeutics, Inc. solve the conditioning chemotherapy problem in CAR T?
  • Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?
  • What the new J-code means for Glaukos’ Epioxa launch and the future of keratoconus reimbursement
  • Molgramostim review pushed to November: what Savara’s FDA delay means for autoimmune PAP
  • What SurGenTec’s TiLink navigation clearance means for surgeons using minimally invasive SI joint fusion systems
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes